Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ATF4 | P18848 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359790 | 0.83 | ATF4 (0.62) | LMNAATF4RAB9AMEN1KMT2A | |
| SCHEMBL21384511 | 0.82 | ATF4 (0.71) | LMNAATF4HPGDHTTRAB9A | |
| Hydrochloric Acid SCHEMBL23294544 | 0.81 | ATF4 (0.69) | LMNAATF4HPGDHTTRAB9A | |
| SCHEMBL21384520 | 0.79 | ATF4 (0.67) | LMNAATF4 | |
| SCHEMBL29689426 | 0.79 | ATF4 (0.60) | LMNAATF4RAB9AMEN1KMT2A | |
| SCHEMBL23702451 | 0.78 | ATF4 (0.66) | LMNAATF4HPGDHTTRAB9A | |
| Trifluoroacetic Acid SCHEMBL21819336 | 0.77 | ATF4 (0.63) | LMNAATF4HPGDHTTRAB9A | |
| SCHEMBL5122821 | 0.77 | LMNA (0.58) | LMNAATF4HPGDHTTRAB9A | |
| SCHEMBL22580361 | 0.76 | LMNA (0.51) | LMNAATF4HPGDHTTRAB9A | |
| SCHEMBL4033699 | 0.76 | ATF4 (0.81) | LMNAATF4HPGDHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | LMNA 3700/4885ATF4 980/4885HPGD 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.